{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:23:57Z","timestamp":1761060237293},"reference-count":37,"publisher":"Lavoisier","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bull. Soc. Pathol. Exot."],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s13149-016-0527-9","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T06:37:59Z","timestamp":1479191879000},"page":"262-271","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Produire de la science en situation de crise. Les traitements m\u00e9dicamenteux sp\u00e9cifiques de la maladie \u00e0 virus Ebola en 2016 : le\u00e7ons et perspectives"],"prefix":"10.3166","volume":"109","author":[{"given":"D.","family":"Malvy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1762","published-online":{"date-parts":[[2016,11,16]]},"reference":[{"key":"527_CR1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(14)61734-7","volume":"384","author":"C Adebamowo","year":"2014","unstructured":"Adebamowo C, Bah-Sow O, Binka F, et al (2014) Randomised controlled trials for Ebola: practical and ethical issues. Lancet 384:1423\u20134","journal-title":"Lancet"},{"key":"527_CR2","volume-title":"Clin Inf Dis","author":"CQ Bai","year":"2016","unstructured":"Bai CQ, Mu JS, Kargbo D, et al (2016) Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705), Sierra Leone, 2014. Clin Inf Dis (accessible en ligne, 23 ao\u00fbt 2016)"},{"key":"527_CR3","first-page":"1","volume-title":"Clin Trials","author":"AH Beavogui","year":"2016","unstructured":"Beavogui AH, Delamou A, Yansane ML, et al (2016) Clinical research during the Ebola virus disease outbreak in Guinea: lessons learned and ways forward. Clin Trials 1\u20136, doi: 10.1177\/1740774515619877"},{"issue":"8","key":"527_CR4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/sim.4780090807","volume":"9","author":"E Bellissant","year":"1990","unstructured":"Bellissant E, Benichou J, Chastang C (1990) Application of the triangular test to phase II cancer clinical trials. Stat Med 9(8):907\u2013917","journal-title":"Stat Med"},{"key":"527_CR5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(15)60232-X","volume":"385","author":"N Bouazza","year":"2015","unstructured":"Bouazza N, Treluyer JM, Foissac F, et al (2015) Favipiravir for children with Ebola. Lancet 385:603\u20134","journal-title":"Lancet"},{"key":"527_CR6","unstructured":"Chimerix. An open-label, multicenter study of the safety and antiviral activity of brincidofovir (BCV, CMX001) for Ebola virus disease. ClinicalTrials.gov. 2014 Oct 7 [cited 15 Aug 2016]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02271347"},{"key":"527_CR7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-3-11","volume":"3","author":"SC Chow","year":"2008","unstructured":"Chow SC, Chang M (2008) Adaptive design methods in clinical trials: a review. Orphanet J Rate Dis 3:11, doi101186\/1750-1172-3-11","journal-title":"Orphanet J Rate Dis"},{"key":"527_CR8","doi-asserted-by":"crossref","first-page":"100181","DOI":"10.1371\/journal.pmed.1001815","volume":"12","author":"BS Cooper","year":"2015","unstructured":"Cooper BS, Boni MF, Pan-Ngum W, et al (2015) Evaluating clinical trial designs for investigational treatments of Ebola virus disease. PLoS Med 12:e100181","journal-title":"PLoS Med"},{"key":"527_CR9","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","volume":"375","author":"RT Davey","year":"2016","unstructured":"Davey RT, Dodd L, Proschan MA, et al (2016) PREVAIL II: a multicenter RCT of Zmapp\u2122 in Ebola virus infection. N Engl J Med 375:1448\u201356.","journal-title":"N Engl J Med"},{"key":"527_CR10","volume-title":"Clin Infect Dis","author":"B Diallo","year":"2016","unstructured":"Diallo B, Sissoko D, Loman NJ, et al (2016) Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days. Clin Infect Dis pii:ciw601 (accessible en ligne, 1er septembre 2016)"},{"issue":"12","key":"527_CR11","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/infdis\/jiw061","volume":"213","author":"LE Dodd","year":"2016","unstructured":"Dodd LE, Proschan MA, Neuhaus J, et al (2016) Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study. J Infect Dis 213(12):1906\u201313","journal-title":"J Infect Dis"},{"key":"527_CR12","doi-asserted-by":"crossref","first-page":"1001997","DOI":"10.1371\/journal.pmed.1001997","volume":"13","author":"J Dunning","year":"2016","unstructured":"Dunning J, Sahr F, Rojek A, et al (2016) Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial. PLoS Med 13:e1001997","journal-title":"PLoS Med"},{"key":"527_CR13","doi-asserted-by":"crossref","first-page":"0162199","DOI":"10.1371\/journal.pone.0162199","volume":"11","author":"J Dunning","year":"2016","unstructured":"Dunning J, Kennedy SB, Antierens A, et al (2016) Experimental treatment of Ebola virus disease with brincidofovir. PLoS One 11:e0162199","journal-title":"PLoS One"},{"key":"527_CR14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","volume":"386","author":"AM Henao-Restrepo","year":"2015","unstructured":"Henao-Restrepo AM, Longini IM, Egger M, et al (2015) Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386:857\u201366","journal-title":"Lancet"},{"key":"527_CR15","unstructured":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, France. Efficacy of favipiravir against Ebola (JIKI). ClinicalTrials.gov. 2014 Dec 16 [cited 15 Aug 2016]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02329054"},{"key":"527_CR16","unstructured":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, France. Tolerance and activity evaluation of high doses of favipiravir against Ebola virus in the semen (FORCE). ClinicalTrials.gov. 2016 Fev 24 [cited 15 Aug 2016]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02739477"},{"key":"527_CR17","unstructured":"Institute of Tropical Medicine, Belgium. Emergency evaluation of convalescent plasma for Ebola viral disease (EVD) in Guinea (Ebola-Tx). ClinicalTrials.gov. 2015 Jan 15 [cited 15 Aug 2016]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02342171"},{"key":"527_CR18","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S1473-3099(15)00228-5","volume":"15","author":"M Jacobs","year":"2015","unstructured":"Jacobs M, Aarons E, Bhagani S, et al (2015) Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. Lancet Infect Dis 15:1300\u20134","journal-title":"Lancet Infect Dis"},{"key":"527_CR19","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1473-3099(15)70106-4","volume":"15","author":"S Lanini","year":"2015","unstructured":"Lanini S, Zumla A, Ioannidis JPA, et al (2015) Are adaptive randomised trials or non-randomised trails studies the best way to address the Ebola outbreak in West Africa? Lancet Infect Dis 15:738\u201345","journal-title":"Lancet Infect Dis"},{"key":"527_CR20","volume-title":"Emergency ethics: public health preparedness and response","author":"AJ London","year":"2015","unstructured":"London AJ (2015) Research in a public health crisis: the integrative approach to managing the moral tensions. In: Jennings B, et al (eds) Emergency ethics: public health preparedness and response. Oxford University Press, New York, NY"},{"key":"527_CR21","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40262-015-0364-1","volume":"55","author":"V Madelain","year":"2016","unstructured":"Madelain V, Nguyen TH, Olivo A, et al (2016) Ebola virus infection: review of the pharmacokinetic and pharmacodynamics properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet 55:907\u201323","journal-title":"Clin Pharmacokinet"},{"key":"527_CR22","first-page":"1515","volume":"198","author":"D Malvy","year":"2014","unstructured":"Malvy D, le groupe d\u2019\u00e9tude JIKI (2014) \u00c9valuation des antiviraux dans la maladie \u00e0 virus Ebola, 2014\u20132015: enjeux et perspectives. Bull Acad Natle Med 198:1515\u201327","journal-title":"Bull Acad Natle Med"},{"key":"527_CR23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(14)71047-3","volume":"15","author":"F Mentre","year":"2014","unstructured":"Mentre F, Taburet AM, Guedj J, et al (2014) Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis 15:150\u20131","journal-title":"Lancet Infect Dis"},{"key":"527_CR24","unstructured":"National Institute of Allergy and Infectious Diseases. Putative investigational therapeutics in the treatment of patients with known Ebola infection. ClinicalTrials.gov. 2015 Feb 13 [cited 15 Aug 2015]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02363322"},{"key":"527_CR25","unstructured":"National Institute of Allergy and Infectious Diseases. GS-5734 to assess the antiviral activity, longer-term clearance of Ebola virus, and safety in male Ebola survivors with evidence of Ebola virus persistence in semen. ClinicalTrials.gov. 2016 Jun 28 [cited 15 Aug 2015]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02818582"},{"key":"527_CR26","doi-asserted-by":"crossref","first-page":"0004393","DOI":"10.1371\/journal.pntd.0004393","volume":"10","author":"R Palich","year":"2016","unstructured":"Palich R, Gala JL, Petitjean F, et al (2016) A 6-year old child with severe Ebola virus disease: laboratory-guided clinical care in an Ebola treatment center in Guinea. PLoS Negl Trop Dis 10:e0004393","journal-title":"PLoS Negl Trop Dis"},{"key":"527_CR27","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1473-3099(14)70956-9","volume":"14","author":"P Piot","year":"2014","unstructured":"Piot P, Muyembe JJ, Edmunds WJ (2014) Ebola in West Africa: from disease outbreak to humanitarian crisis. Lancet Infect Dis 14:1034\u20135","journal-title":"Lancet Infect Dis"},{"key":"527_CR28","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa1411680","volume":"371","author":"JS Schieffelin","year":"2014","unstructured":"Schieffelin JS, Shaffer JG, Goba A, et al (2014) Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 371:2092\u2013100","journal-title":"N Engl J Med"},{"key":"527_CR29","doi-asserted-by":"crossref","first-page":"1001967","DOI":"10.1371\/journal.pmed.1001967","volume":"13","author":"D Sissoko","year":"2016","unstructured":"Sissoko D, Laou\u00e9nan C, Folkesson E, et al (2016) Experimental treatment of favipiravir for Ebola virus disease (the JIKI trial): a historically-controlled, single arm proof-of concept trial in Guinea. PLoS Med 13:e1001967","journal-title":"PLoS Med"},{"key":"527_CR30","unstructured":"University of Oxford. Open-label, single arm trial to investigate the efficacy of TKM-130803 with a concurrent observational study of Ebola virus disease in an outbreak setting in West Africa. PACTR.org. 2015 Jan 16 [cited 15 Aug 2016]. http:\/\/www.pactr.org\/ATMWeb\/appmanager\/atm\/atmregistry?dar=-true&tNo=PACTR201501000997429"},{"key":"527_CR31","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1056\/NEJMoa1504874","volume":"374","author":"TM Uyeki","year":"2016","unstructured":"Uyeki TM, Mehta AK, Davey RT Jr, et al (2016) Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med 374:636\u201346","journal-title":"N Engl J Med"},{"key":"527_CR32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1511812","volume":"374","author":"J Griensven van","year":"2016","unstructured":"van Griensven J, Edwards T, de Lamballerie X, et al (2016) Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 374:33\u201342","journal-title":"N Engl J Med"},{"key":"527_CR33","volume-title":"The Design and Analysis of Sequential Clinical Trials, Revised, 2nd Edition","author":"J Whitehead","year":"1997","unstructured":"Whitehead J (1997) The Design and Analysis of Sequential Clinical Trials, Revised, 2nd Edition. Chichester, UK: John Wiley & Sons Ltd. 328p."},{"key":"527_CR34","volume-title":"Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola","author":"World Health Organization","year":"2014","unstructured":"World Health Organization (2014) Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola (consult\u00e9 le 15 ao\u00fbt 2016). http:\/\/www.who.int\/medicines\/ebola-treatment\/cat_prioritization_drugs_testing\/en\/"},{"key":"527_CR35","volume-title":"Clinical Management of Patients with Viral Haemorrhagic Fever: A Pocket Guide for front-line health workers","author":"World Health Organization","year":"2016","unstructured":"World Health Organization (2016) Clinical Management of Patients with Viral Haemorrhagic Fever: A Pocket Guide for front-line health workers. Second updated version. Geneva, CH: WHO. 203p.","edition":"Second"},{"key":"527_CR36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00134-014-3529-8","volume":"41","author":"Y Yazdanpanah","year":"2015","unstructured":"Yazdanpanah Y, Arribas JR, Malvy D (2015) Treatment of Ebola virus disease. Intensive Care Med 41:115\u2013117","journal-title":"Intensive Care Med"},{"key":"527_CR37","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S1473-3099(15)00344-8","volume":"15","author":"Y Yazdanpanah","year":"2015","unstructured":"Yazdanpanah Y, Horby P, van Griensven J, et al (2015) Drug assessment in the Ebola virus disease epidemic in West Africa. Lancet Infect Dis 15:1258","journal-title":"Lancet Infect Dis"}],"container-title":["Bulletin de la Soci\u00e9t\u00e9 de pathologie exotique"],"original-title":[],"language":"fr","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13149-016-0527-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13149-016-0527-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13149-016-0527-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T19:14:42Z","timestamp":1516994082000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13149-016-0527-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["527"],"URL":"https:\/\/doi.org\/10.1007\/s13149-016-0527-9","relation":{},"ISSN":["0037-9085","1961-9049"],"issn-type":[{"value":"0037-9085","type":"print"},{"value":"1961-9049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}